These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 8027413

  • 1. Comparison of bupropion and trazodone for the treatment of major depression.
    Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA.
    J Clin Psychopharmacol; 1994 Jun; 14(3):170-9. PubMed ID: 8027413
    [Abstract] [Full Text] [Related]

  • 2. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
    Beasley CM, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME.
    J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
    [Abstract] [Full Text] [Related]

  • 3. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [Abstract] [Full Text] [Related]

  • 4. Fluoxetine versus trazodone in the treatment of outpatients with major depression.
    Debus JR, Rush AJ, Himmel C, Tyler D, Polatin P, Weissenburger J.
    J Clin Psychiatry; 1988 Nov; 49(11):422-6. PubMed ID: 3053668
    [Abstract] [Full Text] [Related]

  • 5. A comparison of venlafaxine, trazodone, and placebo in major depression.
    Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E.
    J Clin Psychopharmacol; 1994 Apr; 14(2):99-106. PubMed ID: 8195464
    [Abstract] [Full Text] [Related]

  • 6. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
    Feighner J, Hendrickson G, Miller L, Stern W.
    J Clin Psychopharmacol; 1986 Feb; 6(1):27-32. PubMed ID: 3081600
    [Abstract] [Full Text] [Related]

  • 7. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 9. A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
    Perry PJ, Garvey MJ, Kelly MW, Cook BL, Dunner FJ, Winokur G.
    J Clin Psychiatry; 1989 Aug; 50(8):290-4. PubMed ID: 2668259
    [Abstract] [Full Text] [Related]

  • 10. Long-term therapy for depression with trazodone.
    Fabre LF, Feighner JP.
    J Clin Psychiatry; 1983 Jan; 44(1):17-21. PubMed ID: 6337131
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 12. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 13. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A.
    Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
    [Abstract] [Full Text] [Related]

  • 14. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
    Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KR.
    Obes Res; 2001 Sep; 9(9):544-51. PubMed ID: 11557835
    [Abstract] [Full Text] [Related]

  • 15. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 16. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Aug; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 17. Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results.
    Niederhofer H, Huber M.
    Pharmacotherapy; 2004 Nov; 24(11):1524-8. PubMed ID: 15537557
    [Abstract] [Full Text] [Related]

  • 18. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 19. Trazodone in the treatment of neurotic depression.
    Goldberg HL, Finnerty RJ.
    J Clin Psychiatry; 1980 Dec; 41(12 Pt 1):430-4. PubMed ID: 7440519
    [Abstract] [Full Text] [Related]

  • 20. [Review of studies of trazodone at the Feighner Research Institute in ambulatory and hospitalized patients].
    Feighner JP.
    Encephale; 1986 Oct; 12 Spec No():243-8. PubMed ID: 3816685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.